Humanized Monoclonal Antibody
DM-204 is a novel G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type 2 diabetes and some of the associated complication's. Activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation.
Preclinical studies of DM-204 resulted in superior glucose control (2.6% HbA1c improvement, p=0.0103) compared to approved anti-diabetic drugs included as controls. In addition, DM-204 treated animals demonstrated statistically significant positive effects on blood pressure (25 mm/Hg improvement, p=0.0007), cholesterol (24% improvement, p=0.0156), and heart rate when compared to controls.
DM-204 Potential Target Markets:
DiaMedica’s main focus for DM-204 is currently on Type 2 diabetes and the associated complications of diabetes. The Company also plans to investigate the effects of DM-204 in cancer and anti-infective studies.
Furthermore, due to the chemical make up of the monoclonal antibody, DM-204 could be administered as infrequent as once-a-month.